Flecaine

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flecaine

What is Flecaine? Definition and Classification

Property Description
Active ingredient Flecainide Acetate
Form Oral tablets, Solution for intravenous injection
Pharmacological class Antiarrhythmic Agent (Class IC)
Common use Management of abnormally rapid heart rhythms
Origin Synthetic

1. Defining Flecaine: Active Ingredient and Antiarrhythmic Classification

Flecaine is a specialized, prescription-only medicine containing the single active ingredient Flecainide Acetate, which is used to manage and prevent abnormal heart rhythms. The compound is formally classified as an Antiarrhythmic Agent, a group of drugs designed to regulate the electrical stability of the heart muscle. This designation confirms its primary role in correcting cardiac rhythm disturbances.

Flecainide Acetate is distinguished by its placement within the Vaughan Williams Class IC of antiarrhythmics, indicating a potent and selective mechanism of action that works as a sodium channel blocker. Its Class IC status means it selectively stabilizes cardiac cell membranes by highly specific modulation of the fast inward sodium current. The substance itself is a synthetic agent, manufactured chemically rather than derived from a natural source, and its use is specifically focused on patients without significant structural heart disease.

2. Form, Origin, and General Therapeutic Function

The active ingredient, Flecainide Acetate, is prepared for patient use primarily as oral tablets for maintenance therapy. It is also available as a sterile solution for intravenous injection for administration in acute clinical settings.

The essential therapeutic function of Flecaine is to prevent the recurrence and manage episodes of abnormally rapid or irregular heart rates, clinically known as tachyarrhythmias. A typical use scenario involves stabilizing a heart prone to intermittent episodes of rapid, disorganized beating. By controlling the speed and stability of the heart's electrical conduction pathways, the medicine helps restore a coordinated and efficient rhythm.

What side effects are possible with Flecaine?

Possible Side Effects and Safety Information

The safety profile of Flecaine (Flecainide Acetate), a Class IC antiarrhythmic agent, is officially classified by regulatory authorities based on the frequency and nature of documented adverse reactions. These effects are organized by the physiological system they affect.

Adverse Reactions by Frequency

Classification Examples of Documented Effects
Very Common Dizziness, visual disturbance, blurred vision, or double vision (diplopia).
Common Headache, tremor, nausea, fatigue, asthenia (lack of energy), malaise, dyspnea (shortness of breath), and rash.
Uncommon Increased hepatic enzymes, alopecia, leukopenia, and thrombocytopenia.

Critical Safety Constraints

The most significant safety consideration is the risk of proarrhythmia, which is the potential for the medicine to cause a new or worsened, potentially life-threatening, ventricular arrhythmia. Additionally, there is a risk of exacerbation of congestive heart failure and the development of serious conduction defects, such as second- or third-degree atrioventricular (AV) block.

Regulatory documentation defines specific constraints on use. The drug is contraindicated in patients with pre-existing second- or third-degree AV block (unless a functional pacemaker is present) and in individuals with structural heart disease or a history of myocardial infarction and asymptomatic ventricular arrhythmias. Patients with significant renal or hepatic impairment may also require specialized safety consideration due to altered drug clearance.

Overdose and Emergency Response

Overdose and When to Seek Help

Flecainide is classified by some regulatory authorities as a Narrow Therapeutic Index (NTI) drug. This means there is a small margin between a dose that is effective and one that is toxic, and even a small increase in dosage or blood concentration can potentially lead to serious adverse effects or toxicity. Overdose with this medication is considered a potentially life-threatening medical emergency.

Documented Overdose Symptoms

Overdose may present with a variety of symptoms, most critically affecting the cardiovascular system. Manifestations can include:

  • Cardiac: Slow, fast, or irregular heartbeat; reduced heart muscle contractility; and significant changes in the heart's electrical activity seen on an ECG, such as widened QRS complexes or prolonged PR and QT intervals.
  • Non-Cardiac: Nausea, vomiting, seizures, and loss of consciousness.

Emergency Action

Due to the severity of potential outcomes, including sudden death, immediate medical attention is required in the event of a suspected overdose. Patients who have collapsed, had a seizure, have trouble breathing, or cannot be awakened must receive emergency medical services immediately.

Management in a healthcare setting is symptomatic and supportive, and may involve advanced cardiac and respiratory support. Note that standard treatment such as hemodialysis is not expected to be effective in removing the drug from the body due to its properties.

Therapeutic Uses of Flecaine

Flecaine is an antiarrhythmic medication used to help manage symptoms associated with certain types of abnormal heart rhythms. Its primary role is in the treatment of arrhythmias that originate in the upper chambers of the heart, specifically in clinical scenarios such as paroxysmal supraventricular tachycardias (PSVTs), including those related to Wolff-Parkinson-White syndrome.

The medication is also indicated to help maintain normal sinus rhythm in patients with paroxysmal atrial fibrillation/flutter who have responded to initial therapy. The therapeutic benefit is centered on supporting the heart’s electrical stability, which can help reduce the recurrence and frequency of symptomatic episodes. These symptoms may include feelings of a rapid, racing heart (palpitations) or dizziness.


Quick Fact: Relief for Palpitations and Maintaining Normal Rhythm


Eligibility and Restrictions for Use

Flecaine (flecainide) is an antiarrhythmic medicine with highly restricted use, primarily reserved for patients with life-threatening ventricular arrhythmias or specific, non-structural supraventricular arrhythmias.

Populations That Cannot Use Flecaine (Contraindications)

Flecaine is contraindicated and must not be used by patients with:

  • Structural heart disease, including a history of myocardial infarction (heart attack), severe congestive heart failure, or cardiogenic shock (as this increases the risk of fatal cardiac events).
  • Pre-existing second- or third-degree atrioventricular (AV) block or bundle branch block (bifascicular block), unless a pacemaker is present to sustain cardiac rhythm.
  • Chronic atrial fibrillation (use is not recommended).
  • Known hypersensitivity or allergy to flecainide.

Eligibility Restrictions and Special Considerations

Use requires caution or dose adjustment in specific groups:

  • Age: Safety and efficacy have not been established in the pediatric population. Elderly patients may require dose adjustment due to age-related changes in kidney function.
  • Organ Function: Patients with hepatic (liver) or renal (kidney) impairment may require dose reductions due to slower drug removal from the body.
  • Electrolyte Imbalance: Conditions like low potassium (hypokalemia) or magnesium must be corrected prior to initiating therapy.
  • Pregnancy/Lactation: Use during pregnancy is generally limited to cases where the potential benefit justifies the risk. The drug is known to pass into breast milk.

What should I know about interactions with other medicines?

The use of Flecaine involves significant risks of interaction with other medicines, which can lead to increased side effects, cardiotoxicity, or other serious adverse events.

Potential Pharmacokinetic Interactions

Flecaine is metabolized primarily by the CYP2D6 liver enzyme. Co-administration with drugs that inhibit this enzyme, such as certain antiarrhythmics (e.g., Amiodarone, Quinidine), antidepressants (e.g., Escitalopram), or Cimetidine, can significantly increase the concentration of Flecaine in the bloodstream. This typically requires a dose reduction of Flecaine and careful therapeutic monitoring.

Potential Pharmacodynamic Interactions

  • Additive Cardiac Effects: Concurrent use with other antiarrhythmics, beta-blockers (e.g., Propranolol), or calcium channel blockers (e.g., Verapamil) may result in additive negative inotropic effects (weakening heart muscle contraction) or proarrhythmic effects (causing new or worse arrhythmias).
  • QTc Prolongation: Combining Flecaine with other medications known to prolong the QTc interval (a measure of heart electrical activity) increases the risk of a dangerous, irregular heart rhythm called Torsade de Pointes. Many common medications, including some antipsychotics and HIV protease inhibitors (e.g., Ritonavir), fall into this category, and these combinations are generally contraindicated or should be avoided.

Flecaine may also increase the effects of Digoxin, necessitating a Digoxin dose reduction when used together. Additionally, absorption of Flecaine may be reduced if taken with dairy products such as milk or infant formula.

Mechanism of Action

How Flecaine Works: Mechanism of Action

Flecainide functions primarily as a selective blocker of fast voltage-gated cardiac sodium channels (Nav1.5) . This interaction is frequency-dependent, limiting the rapid influx of positive sodium ions (Na^+) into myocardial cells during the depolarization phase of the action potential. This action directly slows the speed of electrical impulse conduction throughout the heart's electrical pathways, particularly in the His-Purkinje system.

The consequence of the delayed depolarization is a significant prolongation of the effective refractory period (ERP)—the time interval required for the cell membrane to repolarize and become responsive to a new electrical stimulus. This modulation of cardiac electrical properties increases the resistance of the tissue to repetitive, high-frequency electrical firing. The drug also influences ryanodine receptors (RyRs), restricting calcium release events from the sarcoplasmic reticulum that can contribute to ectopic electrical activity, thereby reinforcing the overall electrical refractoriness of the myocardial cell.

Dosage and Administration Information

How to Use Flecaine

Flecaine (Flecainide Acetate) is administered according to strict protocols focusing on dosage, frequency, and specific patient monitoring requirements. Its use is standardized across two main approved routes of administration: oral tablets or oral solution for long-term maintenance, and a sterile solution for intravenous injection reserved for acute, monitored clinical settings.


Standard Adult Dosing and Frequency

The dosage regimen is typically divided into twice-daily (BID) administration, maintaining consistent plasma levels. For the management of paroxysmal arrhythmias, the usual starting oral dose is 50 mg twice daily. This dosage may be adjusted upward, but dose increases must occur no more frequently than every four days to allow the drug to reach steady-state concentration. The maximum daily dose for these supraventricular arrhythmias is 300 mg.

Oral tablets may generally be taken with or without food. The 100 mg tablet strength can be divided to facilitate accurate dosing.


Use Protocols for Specific Populations and Settings

Therapy initiation for sustained ventricular arrhythmias must begin in a hospital setting under specialized supervision. Strict dose limitations are required for older adults and patients with impaired organ function. For individuals with severe renal impairment or certain types of hepatic impairment, the maximum initial daily dose is reduced to 100 mg or less, and frequent plasma level monitoring is mandatory during the titration process.

If an oral dose is missed, the patient should take the dose as soon as possible, but if it is close to the time of the next scheduled dose, the missed dose must be skipped; doses must never be doubled.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flecaine

The research on Flecaine (Flecainide Acetate) primarily consists of controlled clinical trials, systematic reviews, and long-term observational studies focusing on its application in managing specific abnormal heart rhythms. The goal of this evidence is to understand the characteristics and patterns observed in clinical evaluation, particularly in populations without underlying structural heart disease.


Evidence for Managing Atrial Fibrillation and Flutter

Research into AF/AFl involved short-term trials to explore the frequency of conversion to normal sinus rhythm (SR) in acute cases, and long-term studies to monitor rhythm maintenance. For chronic use, researchers examined how long patients remained without episodes. This body of evidence was heavily influenced by an earlier large-scale safety trial (CAST) which was associated with outcomes that constrained the continued evaluation of the medicine in specific high-risk populations.


Evidence for Preventing Supraventricular Tachycardias (PSVTs)

The evidence base for preventing PSVTs is built primarily on earlier, rigorously designed, controlled crossover trials. Studies explored outcomes related to the measured change in the frequency of symptomatic PSVT attacks and monitored the time interval between recurrent episodes. The evidence is limited in some areas, as the majority of the core research for clinical evaluation was conducted some time ago, and contemporary data using modern monitoring techniques are still emerging.


Evidence for Specialized Ventricular Arrhythmias

Research has also examined the use of the medicine for specialized ventricular conditions, such as Idiopathic Premature Ventricular Contractions (PVCs). This evidence generally consists of smaller, prospective observational studies. Findings were based on observations in studies with relatively small sample sizes compared to AF trials, and use was observed in highly restricted populations with structurally normal hearts.


Key Limitations and Unanswered Research Questions

The primary research constraint is the required patient characteristics: the exclusion of individuals with structural heart disease. This strict exclusion means a large portion of the potential cardiac population was not evaluated in the core trials, and the results apply only to the populations studied. Furthermore, long-term effects are not fully established outside of the highly selected patient populations, and comparative evidence against newer alternative treatment options is lacking in some areas.

Key Studies & References PRODUCT MONOGRAPH PrTAMBOCOR (flecainide acetate) Tablets (50 and 100 mg) Antiarrhythmic Agent

Frequently Asked Questions (FAQ)

Common questions about Flecaine (FAQ)


Q: Can Flecaine affect my kidneys or liver over time?

Official documents indicate that the medicine is metabolized by the liver and eliminated through the kidneys. Because of this, dose adjustments are described as necessary for use in patients with pre-existing severe kidney or liver impairment.

Uncommonly reported adverse effects include an increase in hepatic enzymes. This information reinforces the need for appropriate patient monitoring by a healthcare provider while the medicine is being used.


Q: What happens if I miss a dose of Flecaine?

The purpose of taking the medicine on a consistent schedule is to maintain a stable level in your bloodstream for rhythm control. The official guidance states the missed dose should not be doubled to make up for it.

Instead, if it is close to the time for your next scheduled dose, the guidance states to skip the missed dose and resume the regular schedule. If it is not close to the next dose, the instruction is to take the dose as soon as remembered.


Q: Can I take Flecaine if I am taking supplements like magnesium or potassium?

Regulatory documents state that electrolyte imbalances, specifically low levels of potassium or magnesium, must be corrected before starting flecainide because these minerals play a critical role in the heart's electrical stability.

Because maintaining proper electrolyte balance is essential to the medicine's activity, official documents underscore the importance of discussing all supplements with a healthcare provider.


Q: What is the connection between Flecaine and a person's electrolyte levels?

Official information indicates that maintaining corrected electrolyte levels, particularly potassium and magnesium, is necessary when using this drug. Imbalances in these electrolytes may alter the medicine's effectiveness.

Furthermore, imbalances can increase the potential for certain serious adverse cardiac effects, which is why monitoring may be required.


Q: What is the purpose of the regular blood tests often needed when on Flecaine?

The purpose of regular blood tests, or plasma level monitoring, is to help ensure the concentration of the medicine in the blood remains within the defined therapeutic range.

This monitoring helps the healthcare provider guide dosage adjustments and to monitor for signs of potential toxicity.


Q: How long does Flecaine stay in your system after stopping it?

Pharmacokinetic data from official sources describes how long the medicine takes to be cleared by the body. In healthy individuals taking multiple oral doses, the time it takes for half of the medicine to be cleared from the system (half-life) is approximately 13 to 20 hours.


Q: Can I take common cold and flu medications while on Flecaine?

Official drug interaction warnings mention that flecainide should be used cautiously with certain other types of medicines. The use of flecainide alongside certain common cold and flu medications containing sympathomimetic agents (like some decongestants) may increase the risk of adverse cardiac effects, such as palpitations or arrhythmia.


Q: Can Flecaine be safely used by women who are pregnant or breastfeeding?

Official documents state that the use of this medicine during pregnancy is generally considered only when the potential benefit is judged to justify the potential risk. Flecainide is also known to pass into breast milk.

Patient-specific factors always determine the use of medicine in these populations, based on the assessment by a healthcare provider.


Q: What should I do if my usual physical activities seem harder while on Flecaine?

Regulatory guidance recommends that patients report new or worsening symptoms, especially those that are documented adverse effects. Common side effects include fatigue, asthenia (a lack of energy), and shortness of breath (dyspnea).

If physical activities feel significantly harder, official guidance directs the patient to seek advice from a healthcare provider.


Q: Why is it important to tell my dentist I am taking Flecaine?

It is important to inform your dentist because Flecaine may interact with local anesthetics, such as lidocaine, which are commonly used in dental procedures. The combination may potentially result in additive effects on the heart's electrical rhythm.

Official documents advise that caution is needed with this combination to mitigate potential risks.


Q: Does Flecaine make you tired or sleepy?

Official documents list common side effects that may affect a person’s energy levels. These include fatigue, asthenia (a lack of physical energy), and dizziness, which may contribute to a general feeling of being tired.


Q: Can people with high blood pressure take Flecaine?

High blood pressure (hypertension) is not listed as a contraindication in the official documents for flecainide. However, both high blood pressure and low blood pressure (hypotension) have been reported as uncommon adverse effects of the drug itself.


Q: Is Flecaine considered a 'blood thinner'?

No. Flecainide is formally classified as an Antiarrhythmic Agent, specifically a sodium channel blocker, whose function is to regulate heart rhythm. It is not classified as an anticoagulant (a 'blood thinner') and does not have this primary effect.


Q: Why do some patients say they feel their heart racing when they first start Flecaine?

This experience can be due to a potential adverse effect documented in official warnings known as proarrhythmia. This means the medicine could cause a new or worsened heart rhythm problem, which may be felt as a racing heart.

In patients with atrial flutter, the drug may also cause a paradoxical increase in ventricular rate (heartbeat) due to changes in electrical conduction.


Q: Do older adults react differently to Flecaine compared to younger people?

Official documents note that older patients may require dose adjustments compared to younger adults. This is primarily due to age-related changes in kidney function, which can alter how efficiently the medicine is cleared from the body.


Q: Is Flecaine used for anxiety or panic attacks?

No. Flecainide is classified solely as an antiarrhythmic agent, and official indications state it is used only for the management and prevention of specific abnormal heart rhythms.


Q: Can Flecaine affect the results of an EKG or other heart tests?

Yes. Flecainide is known to affect the heart's electrical conduction, which is visible on an electrocardiogram (ECG) as a potential change in measurements.

Specifically, official pharmacodynamics data shows the drug can increase the PR interval and QRS duration.


Q: Is Flecaine addictive or habit-forming?

Flecainide is not classified as a controlled substance by regulatory bodies, and official documentation does not indicate that it is addictive or habit-forming.


Q: Can I take Flecaine if I have a history of asthma or lung problems?

Official labeling documents list shortness of breath (dyspnea) as a common adverse effect, and there are rare reports of lung-related issues like pneumonitis.

Patients with pre-existing lung conditions are advised to discuss this information with their healthcare provider.


Q: Does Flecaine make heart rhythm problems worse before they get better?

Flecainide, like other antiarrhythmics, carries a documented risk of proarrhythmia. This means that in some patients, the medicine may cause a new or worsened, potentially serious heart rhythm problem.

The risk of proarrhythmia is a documented serious consideration that is addressed through appropriate patient monitoring.


Q: Why is Flecaine sometimes prescribed for people without noticeable symptoms?

Official documents and the context of historical research indicate that the medicine has been used in specific populations for asymptomatic non-life-threatening ventricular arrhythmias. The decision to treat an asymptomatic condition depends on the specific clinical diagnosis.


Q: Is there a generic version of Flecaine available?

The active ingredient, Flecainide Acetate, is the subject of FDA regulatory guidance for Abbreviated New Drug Applications (ANDAs), which cover the development and approval of generic drugs.

How should Flecaine be stored and disposed of?

Flecainide Acetate tablets must be stored according to specific regulatory conditions to maintain their stability. The product requires storage at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted temperature excursions up to 30 C [NIH DailyMed].

Official Storage and Disposal Requirements

Item Regulatory Condition
Temperature Range Controlled room temperature (20 C to 25 C) [FDA Label].
Protection Keep in a tight, light-resistant container; protect from moisture [NIH DailyMed].
Child Safety Mandatory to keep out of the reach and sight of children [NIH DailyMed].
Disposal Rule Do not dispose of unused or expired product in household trash or wastewater; use a drug take-back program or consult a pharmacist [NIH MedlinePlus, UK PIL].

The medication must be kept in its original, tightly closed container and protected from light and moisture to prevent degradation. Disposing of unused flecainide should be done through official channels to comply with local regulations and protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flecaine found in:

A-Z Index: